JPRN-UMIN000004610
Recruiting
未知
Clinical prospective study to investigate efficacy and safety of immune-cell therapy for malignant tumors - Prospective Study of immune-cell therapy for malignant tumors
ConditionsMalignant tumor
Overview
- Phase
- 未知
- Intervention
- Not specified
- Conditions
- Malignant tumor
- Sponsor
- Kanazawa university
- Enrollment
- 600
- Status
- Recruiting
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- Not provided
Exclusion Criteria
- •Patients who have: 1\) T cell, NK cell lymphoma and leukemia 2\) HTLV\-I Ab and/or HIV Ab positive (LAK therapy), HIV Ab positive (DC therapy) 3\) interstitial pneumonia, including their history or predisposition of them, 4\) Active autoimmune diseases 5\) Active cardiac disease 6\) Serious drug allergy 7\) Pregnancy woman, or woman with suspected pregnancy, lactating woman 8\) Responsible doctors judged the patient inappropriate for the clinical study
Outcomes
Primary Outcomes
Not specified
Similar Trials
Completed
Not Applicable
Clinical prospective study to investigate efficacy of NK cell therapy for malignant tumors.JPRN-UMIN000008046Seta Clinic Group20
Completed
Not Applicable
Clinical prospective study to investigate efficacy of WT1 peptide (PepTivator(R))-pulsed dendritic cell vaccination therapyMalignant tumor (all HLA types)JPRN-UMIN000009447Seta Clinic Group5
Completed
Not Applicable
The prospective study of the clinical efficacy/adverse event of regorafenib in unresectable metastatic and advanced colorectal cancerColorectal cancerJPRN-UMIN000015404Department of Clinical Oncology, Akita University Hospital50
Active, not recruiting
Not Applicable
Clinical trial to investigate clinical efficacy and tolerability of Tretinoin in actinic keratosis - Tretinoin bei AKactinic keratosisMedDRA version: 9.1Level: LLTClassification code 10000614Term: Actinic keratosisEUCTR2007-000093-23-DEAlmirall Hermal GmbH
Active, not recruiting
Not Applicable
Clinical trial to investigate clinical efficacy and tolerability of Verrumal in actinic keratosis (PoC) - Verrumal in AKEUCTR2006-005432-24-DEHermal Kurt Herrmann GmbH & Co OHG15